Publication & Citation Trends
Most Cited Works
Publications
27 total
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL PDF
Cited by 128
OpenAlex
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial PDF
Cited by 17
OpenAlex
VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)
Cited by 4
OpenAlex
Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.
Cited by 10
OpenAlex
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study PDF
Cited by 7
OpenAlex
Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
Cited by 3
OpenAlex
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs PDF
Cited by 326
OpenAlex
Research Topics
Chronic Lymphocytic Leukemia Research
(18)
Chronic Myeloid Leukemia Treatments
(18)
Platelet Disorders and Treatments
(7)
Eosinophilic Disorders and Syndromes
(6)
Acute Lymphoblastic Leukemia research
(4)
Frequent Co-Authors
Affiliations
Novartis (Switzerland)
Barts Health NHS Trust
Royal London Hospital